Former Vanguard CEO Tim Buckley Joins Pfizer Board, Strengthening Governance and Audit Committees

Pfizer Inc. has elected Mortimer ("Tim") J. Buckley to its Board of Directors, effective immediately after a comprehensive search that started in May 2024. Mr. Buckley, age 55, will also join Pfizer's Governance and Sustainability Committee and Audit Committee. With his appointment, Pfizer’s Board now consists of 14 directors, out of which 13 of them are independent.

Until his retirement in 2024, Tim Buckley was chairman and CEO of Vanguard from 2018. He previously served as Vanguard’s chief investment officer there; he handled the company's internal stocks, bond and money market portfolios, investment research, and methodology. Mr Buckley joined Vanguard in 1991 and held various senior leadership roles, including Chief Information Officer and head of the Retail Investor Group. Additionally, Buckley chaired the Children’s Hospital of Philadelphia board from 2011 to 2017. He holds a Bachelor’s degree in Economics from Harvard College and an MBA from Harvard Business School.

Albert Bourla, Pfizer Chairman and Chief Executive Officer, stated, “We are pleased to welcome Tim Buckley to Pfizer’s Board of Directors. Tim is a widely respected business leader with deep expertise in global investment management, financial markets, and operations and someone who values a shared sense of purpose, all of which will be an asset to Pfizer and our shareholders.” 

“I'm honoured to join Pfizer’s Board of Directors, a group of leaders with distinguished careers in science, government, academia, technology and business. I'm impressed with Pfizer’s dedication to patients and focus on innovation to improve health. I look forward to working with the Board and management to support the breakthroughs that change patients' lives while concurrently driving long-term shareholder value,” said Mr. Buckley.